Gero

Executive Summary

Gero is a Singapore-based preclinical biotech leveraging physics-informed generative AI to decode the fundamental mechanisms of aging from longitudinal health data. Founded in 2020, the company has raised $150M to develop therapeutics that separate irreversible entropy-driven decline from reversible disease processes, enabling the discovery of novel drug candidates for age-related conditions such as fibrosis and neurodegeneration. Gero's platform integrates first-principles physics with machine learning to identify targets and small molecule modulators of aging pathways. With a growing team of 50–200 employees and a robust pipeline of preclinical programs, Gero aims to translate its computational discoveries into clinical candidates that combat aging as a whole, rather than individual diseases. The company's unique approach has attracted significant investor interest and positions it as a leader in the aging biology space. However, as a preclinical entity, Gero faces typical risks associated with target validation and clinical translation. The company's success hinges on advancing its lead programs toward the clinic and demonstrating that its platform can consistently yield effective therapies for age-related diseases.

Upcoming Catalysts (preview)

• Q3 2026Lead Compound IND Filing60% success
• Q4 2026Series D Financing Round75% success
• Q2 2026Publication of Peer-Validated Platform Data80% success